Composition, form of production and packaging
Tablets are white, flat-cylindrical, with a facet and a risk.
calcium gopantenate 250 mg
Auxiliary substances: magnesium basic carbonate, potato starch, calcium stearate, talc.
50 pcs. - polymer cans (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2010.
The mechanism of action is due to the direct influence of the gopantenic acid on the GABA Р±- receptor-channel complex. The drug has nootropic and anticonvulsant action. Increases brain resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines moderate sedation with mild stimulating effect, has an anticonvulsant effect, reduces motor excitability. Increases mental and physical performance. Helps normalize GABA content in chronic alcohol intoxication and subsequent ethanol elimination. Prolongs the effect of novocaine and sulfonamides due to the inhibition of the reactions of their acetylation. It causes inhibition of the pathologically increased vesicle reflex and detrusor tone.
Quickly absorbed from the digestive tract, it penetrates the blood-brain barrier, the greatest concentrations are created in the liver, kidneys, in the wall of the stomach and skin. The time to reach C max is 1 hour. The drug is not metabolized and is excreted unchanged for 48 hours: 67.5% of the dose taken with urine, 28.5% with feces.
- cognitive impairment with organic brain lesions (including the consequences of neuroinfections and craniocerebral injuries);
- schizophrenia with cerebral organic insufficiency;
- cerebrovascular insufficiency, caused by atherosclerotic changes in cerebral vessels;
- extrapyramidal disorders (myoclonus-epilepsy, Houtington's chorea, hepatolenticular degeneration, Parkinson's disease, etc.);
- epilepsy with a delayed mental processes, together with anticonvulsant drugs;
- psycho-emotional overload, reduced mental and physical performance (increased concentration and memorization);
- neurogenic disorders of urination: enuresis, pollakiuria, imperative urges, imperative urinary incontinence;
- children with perinatal encephalopathy, mental retardation with varying degrees of severity, with developmental delay (mental, speech, motor or combination), with various forms of infantile cerebral palsy, hyperkinetic disorders (attention deficit hyperactivity disorder, tics), stuttering clonic form), neurosis-like states. The drug is used in children older than 3 years. At an earlier age, it is recommended that the drug be administered as a syrup.
Calcium gopantenate is used alone or as part of complex therapy. The drug is taken orally 15-30 minutes after eating.
A single dose for adults is 0.25-1 g, for children 0.25-0.5 g, a daily dose for adults is 1.5-3 g, for children 0.75-3 g. The course of treatment lasts from 1 to 4 months, in some cases up to 6 months. After 3-6 months, a repeat course of treatment is possible.
In epilepsy, children are prescribed 0.25-0.5 g 3-4 times / day, adults - 0.5-1 g 3-4 times / day, daily, for a long time (up to 6 months).
With hyperkinesia, the drug is prescribed to children at 0.25-0.5 g 3-6 times / day daily for 1-4 months, adults - 1.5-3 g / day daily for 1-5 months. Children withmental deficiency and oligophrenia drug prescribed 0.5 g 4-6 times / day, daily for 3 months, with a delay in speech development - 0.5 g 3-4 times / day for 2-3 months.
At the consequences of neuroinfections and craniocerebral injuries - 0.25 g 3-4 times / day.
To restore efficiency with increased loads and asthenic conditions - by 0.25 g 3 times / day.
For the treatment of extrapyramidal syndrome caused by taking antipsychotics , the drug is prescribed to adults 0.5-1 g 3 times / day, children - 0.25-0.5 g 3-4 times / day. The course of treatment lasts 1-3 months.
At ticks to children - 0.25 -0.5 g 3-6 times / day, for 1-4 months, adults - 1.5-3 g / day for 1-5 months.
With disorders of urination, the drug is prescribed 2-3 times a day for adults to 0.5-1 g, children - 0.25-0.5 g (daily dose of 25-50 mg / kg).
Tactics of prescribing the drug: increasing the dose for 7-12 days, taking in the maximum dose for 15-40 days and gradually reducing the dose until canceled within 7-8 days. The break between the course of therapy is from 1 to 3 months. In the conditions of long-term treatment, simultaneous administration of the drug with other nootropic and stimulating agents is not recommended. Taking into account the nootropic effect of the drug, it is preferably administered in the morning and afternoon.
The drug is low in toxicity and well tolerated. Allergic reactions (rhinitis, conjunctivitis, skin rashes) are possible. In this case, the drug is canceled. Sleep disturbances or drowsiness, noise head - these symptoms are usually short-lived and do not require drug withdrawal.
- Acute severe kidney disease;
- Pregnancy (I trimester);
- children's age till 3 years;
PREGNANCY AND LACTATION
Contraindicated in the first trimester of pregnancy.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in acute severe kidney disease.
APPLICATION FOR CHILDREN
The drug is used in children older than 3 years. At an earlier age, it is recommended that the drug be administered as a syrup.
The drug is prescribed for children with perinatal encephalopathy, mental retardation of varying severity, with developmental delay (mental, speech, motor or combination), with various forms of infantile cerebral palsy, hyperkinetic disorders (attention deficit hyperactivity disorder, tics), stuttering predominantly clonic form), neurosis-like states.
In the conditions of long-term treatment, simultaneous administration of the drug with other nootropic and CNS-stimulating drugs is not recommended.
Symptoms: increased symptoms of side effects.
Treatment: activated charcoal, gastric lavage, symptomatic therapy.
Prolongs the effect of barbiturates, enhances the effects of anticonvulsant drugs, as well as the means that stimulate the central nervous system, enhances the action of local anesthetics (procaine).
Prevents side effects of phenobarbital, carbamazepine, antipsychotic drugs (neuroleptics).
The action of gopaptenic acid is enhanced in combination with glycine, etidronic acid.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
Keep the drug in a dry, dark place at a temperature of no higher than 25 В° C. Keep out of the reach of children. Shelf life - 3 years. Do not use after the expiration date printed on the package.